-
JCO: The efficacy and safety of Lifileucel (a treatment based on tumor infiltrating lymphocytes) in metastatic melanoma
Time of Update: 2021-05-20
Lifileucel treatment is effective for metastatic melanoma, including patients who are resistant to PD1 or PDL1 inhibitors.
Lifileucel treatment is effective for metastatic melanoma, including patients who are resistant to PD1 or PDL1 inhibitors.
-
Eur J Cancer: First-line immune checkpoint inhibitor combination therapy can significantly improve the clinical prognosis of metastatic urothelial cancer
Time of Update: 2021-05-20
ICI monotherapy does not improve the tumor prognosis of patients compared with chemotherapy alone, but the safety prognosis is relatively goodIn summary, the analysis suggests that mUC patients who are eligible for chemotherapy are better than standard chemotherapy when using ICI combination therapy as a first-line treatment plan .
-
J Immunother Cancer: Shocked!
Time of Update: 2021-05-20
1136/jitc-2021-002535" target="_blank" rel="noopener">Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis .
-
NEJM: The effect of anti-B cell maturation antigen CAR-T cell therapy bb2121 in the treatment of multiple myeloma
Time of Update: 2021-05-20
gov/31042825/" target="_blank" rel="noopener">Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma .
gov/31042825/" target="_blank" rel="noopener">Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma in this message
-
Cell Stem Cell: Suppress cancer from the root: Academician Wang Cunyu's team confirmed that blocking CD276 can eliminate cancer stem cells
Time of Update: 2021-05-20
Similar to the use of immune checkpoint inhibitors, the research team injected anti-CD276 antibodies into mouse models of head and neck squamous cell carcinoma to see whether this treatment can block immune checkpoints and inhibit the growth and spread of cancer.
-
JNCCN: The efficacy of treatment with abecilil after the progression of the CDK4/6 inhibitor piperisil in breast cancer patients: multi-center clinical experience
Time of Update: 2021-05-20
The current study confirms that three CDK4/6 inhibitor drugs (pibaciclib, abeciclib, ribociclib) combined with endocrine therapy can improve the progression-free survival (PFS) of HR+/HER2-MBC.
The current study confirms that three CDK4/6 inhibitor drugs (pibaciclib, abeciclib, ribociclib) combined with endocrine therapy can improve the progression-free survival (PFS) of HR+/HER2-MBC.
-
JCO: Levatinib may be used to treat advanced gastrointestinal pancreatic neuroendocrine tumors!
Time of Update: 2021-05-20
To evaluate the efficacy and safety of lenvatinib in patients with advanced GEP-NETs who have previously been treatedThis is a multi-center, single-arm, open-label Phase II clinical trial, divided into two parallel cohorts, involving 21 units in 4 European countries.
-
Liver Cancer: Pembrolizumab (Pembrolizumab) second-line application in advanced liver cancer efficacy: subgroup analysis results from KEYNOTE-240 Asian population
Time of Update: 2021-05-20
Treatment-related adverse eventsIn summary, pembrolizumab is effective in the second-line treatment of advanced liver cancer in Asian population and the toxicity is tolerable.
In summary, pembrolizumab is effective in the second-line treatment of advanced liver cancer in Asian populations and the toxicity is tolerable.
-
Lancet Oncol: Ipilimumab combined with anti-PD-1 therapy significantly improved the clinical prognosis of patients with advanced melanoma resistant to PD-1
Time of Update: 2021-05-20
Two reported grade 3-5 adverse events similar proportion of patients with immuneTo sum up, in patients with melanoma who are resistant to anti-PD-(L)1 therapy, the efficacy of ipilimumab combined with anti-PD-1 therapy is significantly higher than that of ipilimumab monotherapy, which not only improves the objective remission rate, but also Both progression-free survival and overall survival were significantly prolonged .
-
Nature: The Nobel Prize winner recently discovered that organisms can actually squeeze to remove cancer cells, bringing new ideas for cancer treatment
Time of Update: 2021-05-20
On May 5, 2021, the Nobel Prize winner and MIT Professor Robert Horvitz team published a research paper titled: Replication stress promotes cell elimination by extrusion in the Nature journal.
-
J Thorac Oncol: Phase 3 clinical trial results of niraparib as the first-line maintenance treatment for platinum-sensitive patients with extensive-stage small cell lung cancer in China
Time of Update: 2021-05-20
ZL-2306-005 is a randomized, double-blind, multicenter phase 3 study to evaluate the use of the PARP inhibitor niraparib as a platinum-sensitive extensive-stage small cell lung cancer (ES-SCLC) patient in China The effectiveness and safety of the first-line maintenance treatment.
-
J Immunother Cancer: The dynamic changes of tumor-infiltrating immune cells can predict the patient's response to neoadjuvant chemotherapy
Time of Update: 2021-05-20
com/content/9/5/e002198" target="_blank" rel="noopener">Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial Journal for ImmunoTherapy of Cancer 2021;9:e002198.
-
Br J Cancer: GNG4, a potential therapeutic target for liver metastases from gastric cancer
Time of Update: 2021-05-20
In this study, the researchers conducted transcriptomic analysis of liver metastases, primary tumors and adjacent tissues in patients with liver metastasis to gastric cancer, aiming to discover new genes that promote liver metastasis in an organ-oriented method, and for advanced gastric cancer Treatment provides a certain theoretical basis.
-
JAMA Oncol: Both advanced molecular thyroid tests can reduce the need for diagnostic surgery
Time of Update: 2021-05-20
A new study compares the performance characteristics of RNA testing and DNA RNA testing to predict the risk of malignancy for approximately 20% of thyroid nodules that show uncertain fine-needle aspiration (FNA) cytology results.
-
Annual Reviews of Immunology: Zhang Zemin from Peking University reviewed the progress and application of single cell technology in the field of tumor microenvironment and immunotherapy
Time of Update: 2021-05-20
: Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor MicroenvironmentThis review system summarizes the recent research progress of single-cell transcriptome technology in the analysis of tumor microenvironment, including the new characteristics of infiltrating T cells and myeloid immune cells, as well as its application and potential in revealing tumor immunotherapy mechanisms.
-
JCO: Pertuzumab combined with high-dose trastuzumab is expected to improve the prognosis of HER2-positive breast cancer patients with brain metastases
Time of Update: 2021-05-20
With the successive clinical application of trastuzumab and pertuzumab, the prognosis of patients with HER2-positive breast cancer has been significantly improved.
This article reports the efficacy and safety evaluation of Pertuzumab combined with high-dose trastuzumab in HER2-positive breast cancer patients with brain metastases.
-
Journal of Nuclear Medicine: US single-center study found that black prostate cancer 68Ga-PSMA-11 PET imaging is less likely to be used
Time of Update: 2021-05-20
Among patients undergoing molecular imaging examinations for prostate cancer at a single higher medical center in the United States, through clinical trials, black patients have a significantly limited chance of obtaining 68 Ga-PSMA-11 PET compared with non-Hispanic white patients , nearly four times.
-
J Thorac Oncol: miR-17 down-regulates LKB1, suggesting that NSCLC patients with poor prognosis can be treated with energy stress
Time of Update: 2021-05-20
005" target="_blank" rel="noopener">LKB1 down-modulation by miR-17 identifies NSCLC patients with worse prognosis eligible for energy-stress based treatments .
005" target="_blank" rel="noopener">LKB1 down-modulation by miR-17 identifies NSCLC patients with worse prognosis eligible for energy-stress based treatments in this message
-
J Immunother Cancer: Radiotherapy combined with anti-PD-1 therapy before surgery can improve the pathological remission rate of advanced head and neck cancer
Time of Update: 2021-05-20
1136/jitc-2021-002485">Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma .
-
Nat Commun: BCMA/CS1 bispecific CAR can prevent antigen escape during CAR-T treatment of MM
Time of Update: 2021-05-20
gov/32385241/" target="_blank" rel="noopener">Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma .
gov/32385241/" target="_blank" rel="noopener">Systematically optimized BCMA / CS1 bispecific CAR- T cells robustly control heterogeneous multiple myeloma in this message